Anti-interleukin-23 for psoriasis in elderly: guselkumab, risankizumab and tildrakizumab in real world practice.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and experimental dermatology"
DOI: 10.1111/ced.14979
Abstract: BACKGROUND Elderly patients (≥65 years) represent an increasing rate of psoriatic patients, 15% have moderate-to-severe disease. Biologics are being frequently used even if safety and efficacy data are limited. OBJECTIVE Evaluate and compare guselkumab, risankizumab,… read more here.
Keywords: risankizumab tildrakizumab; guselkumab risankizumab; risankizumab; practice ... See more keywords